Standard BioTools (NASDAQ:LAB) Director Casdin Partners Master Fund, L Acquires 375,000 Shares

Standard BioTools Inc. (NASDAQ:LAB) Director Casdin Partners Master Fund, L acquired 375,000 shares of the company’s stock in a transaction that occurred on Wednesday, November 12th. The shares were acquired at an average price of $1.19 per share, with a total value of $446,250.00. Following the acquisition, the director owned 62,050,000 shares in the company, valued at $73,839,500. This trade represents a 0.61% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

Casdin Partners Master Fund, L also recently made the following trade(s):

• On Tuesday, November 11th, Casdin Partners Master Fund, L bought 300,000 shares of Standard BioTools stock. The stock was acquired at an average price of $1.20 per share, for a total transaction of $360,000.00.
• On Monday, November 10th, Casdin Partners Master Fund, L bought 275,000 shares of Standard BioTools stock. The shares were acquired at an average price of $1.17 per share, with a total value of $321,750.00.
• On Friday, November 7th, Casdin Partners Master Fund, L bought 225,000 shares of Standard BioTools stock. The shares were bought at an average cost of $1.12 per share, with a total value of $252,000.00.
• On Tuesday, September 9th, Casdin Partners Master Fund, L purchased 100,000 shares of Standard BioTools stock. The stock was bought at an average price of $1.29 per share, for a total transaction of $129,000.00.
• On Wednesday, September 3rd, Casdin Partners Master Fund, L acquired 250,000 shares of Standard BioTools stock. The shares were bought at an average price of $1.27 per share, with a total value of $317,500.00.
• On Tuesday, August 26th, Casdin Partners Master Fund, L acquired 125,000 shares of Standard BioTools stock. The stock was bought at an average cost of $1.26 per share, with a total value of $157,500.00.
• On Monday, August 25th, Casdin Partners Master Fund, L acquired 200,000 shares of Standard BioTools stock. The stock was bought at an average cost of $1.24 per share, with a total value of $248,000.00.
• On Friday, August 22nd, Casdin Partners Master Fund, L bought 200,000 shares of Standard BioTools stock. The shares were bought at an average cost of $1.26 per share, for a total transaction of $252,000.00.
• On Friday, August 15th, Casdin Partners Master Fund, L purchased 150,000 shares of Standard BioTools stock. The shares were bought at an average cost of $1.22 per share, with a total value of $183,000.00.
• On Thursday, August 14th, Casdin Partners Master Fund, L purchased 133,220 shares of Standard BioTools stock. The stock was purchased at an average price of $1.21 per share, with a total value of $161,196.20.

Standard BioTools Stock Down 0.8%

Shares of NASDAQ:LAB opened at $1.18 on Thursday. The business’s 50 day moving average is $1.29 and its 200 day moving average is $1.23. The stock has a market cap of $453.79 million, a P/E ratio of -3.69 and a beta of 1.25. Standard BioTools Inc. has a 52-week low of $0.92 and a 52-week high of $2.25.

Hedge Funds Weigh In On Standard BioTools

Large investors have recently added to or reduced their stakes in the company. Teacher Retirement System of Texas purchased a new stake in shares of Standard BioTools during the first quarter valued at about $35,000. CWM LLC raised its stake in shares of Standard BioTools by 101.8% during the 1st quarter. CWM LLC now owns 29,705 shares of the company’s stock worth $32,000 after acquiring an additional 14,984 shares in the last quarter. Impact Partnership Wealth LLC purchased a new stake in Standard BioTools during the first quarter valued at approximately $58,000. Royce & Associates LP lifted its position in Standard BioTools by 37.4% during the first quarter. Royce & Associates LP now owns 2,000,503 shares of the company’s stock valued at $2,161,000 after acquiring an additional 545,000 shares during the last quarter. Finally, ARK Investment Management LLC boosted its stake in Standard BioTools by 3.9% in the first quarter. ARK Investment Management LLC now owns 3,452,890 shares of the company’s stock valued at $3,729,000 after acquiring an additional 129,201 shares in the last quarter. 53.74% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

Several equities analysts have recently commented on LAB shares. Weiss Ratings restated a “sell (d-)” rating on shares of Standard BioTools in a research note on Wednesday, October 8th. Wall Street Zen cut shares of Standard BioTools from a “hold” rating to a “strong sell” rating in a report on Saturday, November 8th. Cowen lowered shares of Standard BioTools from a “buy” rating to a “hold” rating in a report on Wednesday, August 13th. Finally, TD Cowen lowered their price target on shares of Standard BioTools from $1.55 to $1.35 and set a “hold” rating for the company in a research report on Wednesday, November 5th. Three equities research analysts have rated the stock with a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Reduce” and a consensus price target of $1.35.

Standard BioTools Company Profile

Standard BioTools Inc, together with its subsidiaries, provides instruments, consumables, reagents, and software services for researchers and clinical laboratories in the Americas, Europe, the Middle East, Africa, and the Asia pacific. It operates through two segments: Proteomics and Genomics. The company offers analytical systems, such as CyTOF XT System, a CyTOF XT mass cytometry system performs automated high-parameter single-cell analysis using antibodies conjugated to metal isotopes; and Hyperion XTi imaging system, a spatial biology instrument.